The 2022 Tandem Meetings | Challenges in CAR-T therapy for myeloid malignancies
Bhagirathbhai Dholaria
• 24 Apr 2022
Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, discusses some of the key obstacles to developing CAR-T therapies for myeloid malignancies. To being with, the most commonly expressed antigens in acute myeloid leukemia (AML) are also expressed on normal hematopoietic stem cells (HSCs), which can lead to off-target effects with CAR-T therapy. In addition, patients with myeloid malignancies have a poor immune microenvironment and have often received prior allogeneic transplantation. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
